Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(13%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph not_applicable
3
19%
Ph phase_3
2
13%
Ph phase_4
7
44%
Ph early_phase_1
1
6%
Ph phase_1
1
6%

Phase Distribution

2

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Early Phase 1First-in-human
1(7.1%)
Phase 1Safety & dosage
1(7.1%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
7(50.0%)
N/ANon-phased studies
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)
Other(4)

Detailed Status

Completed9
unknown4
Terminated1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.1%)
Phase 11 (7.1%)
Phase 32 (14.3%)
Phase 47 (50.0%)
N/A3 (21.4%)

Trials by Status

terminated16%
completed956%
unknown425%
active_not_recruiting16%
recruiting16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT03845049Phase 3

Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

Terminated
NCT06132035Phase 1

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Recruiting
NCT02645266Not Applicable

Mean Visual Acuity Changes Following Five Injections of Aflibercept

Active Not Recruiting
NCT03709745Phase 4

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Completed
NCT06330220Phase 4

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Completed
NCT06205979Early Phase 1

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Unknown
NCT05342857

Maximum Treatment Interval With Aflibercept T&E

Unknown
NCT03651011Not Applicable

Navigated Laser In Branch Retinal Vein Occlusion Study

Completed
NCT03297684

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Unknown
NCT04288232Phase 3

Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

Completed
NCT04153253Phase 4

Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Completed
NCT03974425Not Applicable

One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab

Completed
NCT03197480Phase 4

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

Unknown
NCT03804099Phase 4

Effect Aflibercept on Ocular Perfusion

Completed
NCT03453281Phase 4

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

Completed
NCT03355638Phase 4

Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16